



Correction to: A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy

Thorsten Rosenbaum¹ · Pia Vaassen¹

Published online: 29 July 2023

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

Correction to: Childs Nerv Syst. 2023 Jun 21.

<https://doi.org/10.1007/s00381-023-06029-5>. Epub ahead of print. PMID: 37344677

In the discussion section of this article we referred to a recent case report that had allegedly demonstrated development of a MPNST during on-going selumetinib therapy. We would like to clarify that the patients described in the cited case report were not on selumetinib therapy but were treated with trametinib. However, this does not change our conclusion that MEK inhibition in general might not be sufficient to prevent malignancy in NF1-PN.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00381-023-06029-5>.

✉ Pia Vaassen
pia.vaassendr@sana.de

¹ Department of Pediatrics, Sana Kliniken Duisburg, Germany